978 related articles for article (PubMed ID: 18347167)
1. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
2. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I; Deubzer HE; Wegener D; Pickert D; Linke JP; Hero B; Kopp-Schneider A; Westermann F; Ulrich SM; von Deimling A; Fischer M; Witt O
Clin Cancer Res; 2009 Jan; 15(1):91-9. PubMed ID: 19118036
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
5. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3.
Thangaraju M; Carswell KN; Prasad PD; Ganapathy V
Biochem J; 2009 Jan; 417(1):379-89. PubMed ID: 18789002
[TBL] [Abstract][Full Text] [Related]
6. HDAC expression and clinical prognosis in human malignancies.
Weichert W
Cancer Lett; 2009 Aug; 280(2):168-76. PubMed ID: 19103471
[TBL] [Abstract][Full Text] [Related]
7. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Huang BH; Laban M; Leung CH; Lee L; Lee CK; Salto-Tellez M; Raju GC; Hooi SC
Cell Death Differ; 2005 Apr; 12(4):395-404. PubMed ID: 15665816
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
10. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
12. HDAC3 overexpression and colon cancer cell proliferation and differentiation.
Spurling CC; Godman CA; Noonan EJ; Rasmussen TP; Rosenberg DW; Giardina C
Mol Carcinog; 2008 Feb; 47(2):137-47. PubMed ID: 17849419
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Krusche CA; Wülfing P; Kersting C; Vloet A; Böcker W; Kiesel L; Beier HM; Alfer J
Breast Cancer Res Treat; 2005 Mar; 90(1):15-23. PubMed ID: 15770522
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Harms KL; Chen X
Cancer Res; 2007 Apr; 67(7):3145-52. PubMed ID: 17409421
[TBL] [Abstract][Full Text] [Related]
15. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.
Göttlicher M
Ann Hematol; 2004; 83 Suppl 1():S91-2. PubMed ID: 15124690
[TBL] [Abstract][Full Text] [Related]
17. Negative and positive regulation of gene expression by mouse histone deacetylase 1.
Zupkovitz G; Tischler J; Posch M; Sadzak I; Ramsauer K; Egger G; Grausenburger R; Schweifer N; Chiocca S; Decker T; Seiser C
Mol Cell Biol; 2006 Nov; 26(21):7913-28. PubMed ID: 16940178
[TBL] [Abstract][Full Text] [Related]
18. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Lee AY; Paweletz CP; Pollock RM; Settlage RE; Cruz JC; Secrist JP; Miller TA; Stanton MG; Kral AM; Ozerova ND; Meng F; Yates NA; Richon V; Hendrickson RC
J Proteome Res; 2008 Dec; 7(12):5177-86. PubMed ID: 19367703
[TBL] [Abstract][Full Text] [Related]
20. Expression and functional characterization of recombinant human HDAC1 and HDAC3.
Li J; Staver MJ; Curtin ML; Holms JH; Frey RR; Edalji R; Smith R; Michaelides MR; Davidsen SK; Glaser KB
Life Sci; 2004 Apr; 74(22):2693-705. PubMed ID: 15043985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]